Relay Therapeutics (NASDAQ:RLAY) & Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head Comparison

Relay Therapeutics (NASDAQ:RLAY) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares Relay Therapeutics and Monte Rosa Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35 million	403.56	-$276.48 million	($1.57)	-12.14
Monte Rosa Therapeutics	$123.67 million	9.59	-$38.63 million	($1.76)	-7.90

Monte Rosa Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Relay Therapeutics and Monte Rosa Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1	1	10	2	2.93
Monte Rosa Therapeutics	1	1	6	1	2.78

Relay Therapeutics currently has a consensus target price of $25.92, suggesting a potential upside of 35.97%. Monte Rosa Therapeutics has a consensus target price of $28.50, suggesting a potential upside of 105.04%. Given Monte Rosa Therapeutics’ higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Relay Therapeutics.

Profitability

This table compares Relay Therapeutics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Risk & Volatility

Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Summary

Relay Therapeutics beats Monte Rosa Therapeutics on 9 of the 15 factors compared between the two stocks.

About Relay Therapeutics

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.